Why the study?
Does moricizine increase pacing threshold in patients with an AICD?
Does moricizine increase pacing threshold in patients with an AICD?
Moricizine therapy can lead to an increased ventricular pacing threshold and symptomatic bradycardia in patients with an AICD.
Answers are grounded in this paper and cite their sources.
Moricizine may increase pacing threshold and cause bradycardia in AICD patients; single case leaves open prospective confirmation.
A 72-year-old woman who was experiencing incessant ventricular tachycardia and recurrent automatic implantable cardioverter defibrillator (AICD) firing despite amiodarone therapy was referred to the Cleveland Clinic Foundation. Myocardial ischemia and infarction were ruled out by standard means. Several antiarrhythmic medications were tried previously without success. Moricizine, 200 mg three times daily, was initiated and controlled the ventricular tachycardia. However, after the dose of moricizine was titrated upward, the patient became symptomatically bradycardic and the ECG exhibited 2:1 block of her paced rhythm and an increased ventricular pacing threshold.
No takes yet. Share an insight, caveat, or question.
Girod et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: